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Elisabeth Rushing5, Jennifer Eschbacher6, Nhan L Tran3, Amanda Chan1* and Marc Symons1,2,7*
Abstract
Background: The invasion of glioblastoma cells into regions of the normal brain is a critical factor that limits
current therapies for malignant astrocytomas. Previous work has identified roles for the Rho family guanine
nucleotide exchange factors Trio and Vav3 in glioblastoma invasion. Both Trio and Vav3 act on the small GTPase
RhoG. We therefore examined the role of RhoG in the invasive behavior of glioblastoma cells.
Results: We found that siRNA-mediated depletion of RhoG strongly inhibits invasion of glioblastoma cells through
brain slices ex vivo. In addition, depletion of RhoG has a marginal effect on glioblastoma cell proliferation, but
significantly inhibits glioblastoma cell survival in colony formation assays. We also observed that RhoG is activated
by both HGF and EGF, two factors that are thought to be clinically relevant drivers of glioblastoma invasive
behavior, and that RhoG is overexpressed in human glioblastoma tumors versus non-neoplastic brain. In search of a
mechanism for the contribution of RhoG to the malignant behavior of glioblastoma cells, we found that depletion
of RhoG strongly inhibits activation of the Rac1 GTPase by both HGF and EGF. In line with this observation, we also
show that RhoG contributes to the formation of lamellipodia and invadopodia, two functions that have been
shown to be Rac1-dependent.
Conclusions: Our functional analysis of RhoG in the context of glioblastoma revealed a critical role for RhoG in
tumor cell invasion and survival. These results suggest that targeting RhoG-mediated signaling presents a novel
avenue for glioblastoma therapy.
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Background
Rho family small GTPases are key signaling elements that
control the malignant behavior of cancer cells [1]. In par-
ticular, a number of these GTPases have been shown to
regulate cell proliferation, survival and invasion [2,3].
Most Rho GTPases act like molecular switches that are
active when bound to GTP and inactive when bound to
GDP [4]. Their activation is catalyzed by guanine nucleo-
tide exchange factors (GEFs) that induce nucleotide
release, allowing for the more abundant cytoplasmic GTP
to be loaded onto the GTPase. GTPases are inactivated by
GTPase activating proteins (GAPs), which stimulate in-
trinsic GTP hydrolysis.
Glioblastoma multiforme (grade IV astrocytoma) is
one of the most aggressive of all human cancers, with a
median survival time of little more than one year [5].
Despite aggressive treatment and recent clinical and mo-
lecular advances, the overall survival of glioblastoma
patients has not significantly improved over the past two
decades. Malignant gliomas, in addition to a core mass,
display extensive infiltration of individual cells into the
normal brain parenchyma [6]. These invading cells are
highly resistant to radiation and chemotherapy, thereby
leading to recurrence [7,8]. Furthermore, although anti-
angiogenic therapy for recurrent glioblastoma using bev-
acizumab increases patient survival, it also increases
tumor invasiveness [9]. Thus, tumor dispersal is a crit-
ical problem in the treatment of these brain tumors and
currently, there are no anti-invasive therapies available.
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Thus far, the only Rho family GTPases that have been
functionally characterized in glioblastoma cells are Rac1,
and to a lesser extent, Rac3 [10-12]. Thus, we have
shown that Rac1 regulates glioblastoma cell invasion
and proliferation [10,11]. In addition, plasma membrane
localization of Rac1 in glioblastoma cells in situ indicates
that Rac1 is constitutively active in a subset of these
tumors [12]. We also have identified roles for the Rho
family GEFs Trio and Vav3 in the invasive behavior of
glioblastoma cells [12]. Both Trio and Vav3 act on the
small GTPase RhoG [13,14]. RhoG remains one of the
less characterized Rho family members and its role in
tumor cells is largely unexplored. RhoG was identified as
a growth factor response gene [15] and has also been
shown to regulate cell migration, neurite outgrowth and
cell survival [16-18]. The signaling elements, including
receptors and GEFs, that mediate RhoG activation
largely remain to be identified [19].
In this paper, we focus on the role of RhoG in the in-
vasive behavior of glioblastoma cells. We show that
RhoG is critical for glioblastoma cell invasion, both
in vitro and in ex vivo brain slices. We also demonstrate
that RhoG mediates signaling that is stimulated by cMet
and EGFR, two receptors that are deregulated in glio-
blastoma tumors and that RhoG is overexpressed in
human glioblastoma tumor tissue versus non-neoplastic
brain.
Results
RhoG mediates glioblastoma cell invasion
To examine the role of RhoG in glioblastoma invasion
we first determined the effect of depleting RhoG on the
invasion of glioblastoma cells into rodent brain slices, a
well-established organotypic model [20]. We found that
siRNA-mediated depletion of RhoG, using two inde-
pendent oligos to minimize the risk of RNA off-target
effects, strongly impairs invasion of two glioblastoma
cell lines, SNB19 and U87, into brain tissue (Figure 1A).
Both siRNAs strongly inhibit RhoG expression
(Figure 1B).
As RhoG has been shown to promote the proliferation
of neural progenitor cells in the mouse cerebral cortex
[21], we also examined whether RhoG contributes to the
proliferative behavior of glioblastoma cells, as this could
be a possible confounding factor in the evaluation of
glioblastoma cell invasiveness. We observed that deple-
tion of RhoG has a small inhibitory effect on the prolif-
eration of glioblastoma cells over a 5 day period in the
presence of serum, but does not affect cell proliferation
over the time period in which the brain slice invasion
experiments are carried out (2 days) (Figure 1C). In
addition, depletion of RhoG has no significant effect on
cell proliferation in the absence of serum (Figure 1D).
RhoG regulates glioblastoma cell invasion using both
Rac1-dependent and Rac1-independent mechanisms
To start dissecting the signaling mechanisms that are
mediated by RhoG in glioblastoma, we first examined
whether RhoG is activated by HGF (hepatocyte growth
factor, also known as scatter factor). HGF is the most
potent chemotactic factor known for glioblastoma cells
[22]. In addition, expression levels of HGF and its recep-
tor cMet correlate with astrocytoma grade [23,24]. Im-
portantly, interference with cMet signaling, either using
ribozymes targeting HGF or cMet, or a cMet-targeting
small molecule, inhibits glioblastoma tumor growth
in vivo [25,26]. Stimulation of SNB19 cells with HGF
activates RhoG within 2 minutes and subsequently
declines (Figure 2A).
RhoG has been shown to act upstream of the Rac1
small GTPase [27,28] and Rac1 is also known to be acti-
vated by HGF [29]. We therefore examined whether
RhoG mediates HGF-induced Rac1 activation in glio-
blastoma cells. Rac1 activation was determined using an
ELISA assay that quantifies the amount of Rac proteins
in cell lysates through binding to an immobilized Rac ef-
fector [30]. Since Rac1 is the major Rac isoform
expressed in glioma cells, this assay essentially reports
on the activation state of Rac1 [10]. We found that
HGF-induced Rac1 activation in SNB19 cells peaks at
around 4 minutes, significantly slower than the kinetics
of RhoG activation (Figure 2B). We also observed that
depletion of RhoG significantly inhibits HGF-stimulated
Rac1 activation. These results indicate that RhoG indeed
functions upstream of Rac1 in HGF-stimulated cells,
consistent with the observation that HGF-induced acti-
vation of RhoG precedes that of Rac1.
We also examined whether depletion of RhoG modu-
lates the expression of Rac1, as this would complicate
our analysis. We found that depletion of RhoG does not
affect expression of Rac1 nor vice versa.
Interestingly, depletion of RhoG only partially inhibits
HGF-stimulated Rac1 activity (by approximately 40%),
indicating the existence of RhoG-independent signaling
mechanisms that contribute to Rac1 activation in this
context. In contrast, depletion of RhoG largely abolishes
HGF-induced invasion of SNB19 cells in a three-
dimensional Matrigel invasion assay. This inhibitory ef-
fect is as large as that caused by depletion of Rac1
(Figure 3).
To examine whether partial inhibition of HGF-
stimulated Rac1 activation, similar to that caused by
depletion of RhoG, could be sufficient to block HGF-
induced invasion, we transfected SNB19 cells with a
range of Rac1 siRNA concentrations. Interestingly, we
observed that depletion of Rac1 by up to 60%, which
inhibits Rac1 activation by at least 50%, does not cause
significant inhibition of cell invasion (Figure 4). This
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implies that Rac1-mediated invasion depends on a
threshold of Rac1 expression. Thus, taken together, the
results shown in Figures 3 and 4 strongly suggest that
RhoG regulates glioblastoma cell invasion via both
Rac1-dependent and Rac1-independent mechanisms.
To further explore the mechanisms that mediate
RhoG-regulated glioblastoma cell invasion, we examined
the role of RhoG in the formation of two structures that
have been implicated in Rac1-regulated cell migration
and invasion: invadopodia and lamellipodia. We also
compared depletion of RhoG with that of Rac1 under
the same conditions. Whereas depletion of Rac1 com-
pletely abrogates HGF-induced lamellipodia formation
in SNB19 cells, as observed previously for serum-
stimulated lamellipodia formation in these cells [10], de-
pletion of RhoG has a much smaller inhibitory effect on
this function (Figure 5A, B). Surprisingly, we noted that
the extent of membrane ruffling, as defined by lamelli-
podia that lift off from the substrate and fold back to-
ward the center of the cell, is actually stimulated by
depletion of RhoG, whereas depletion of Rac1, as
expected, strongly inhibits ruffle formation.
Depletion of RhoG significantly inhibits invadopodia
formation, but less efficiently than depletion of Rac1
(Figure 5C). Taken together, the observations that deple-
tion of RhoG strongly inhibits glioblastoma cell invasion,
but only partially inhibits the formation of invadopodia
and lamellipodia, further supports the conclusion that
RhoG regulates glioblastoma cell invasion using both
Rac1-dependent and -independent mechanisms.
RhoG mediates EGF-stimulated Rac1 activation
A recent study has demonstrated that RhoG is activated
downstream of the EGF receptor (EGFR) [19]. Since
EGFR is amplified and/or mutated in 45% of all
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Figure 1 RhoG is necessary for glioblastoma cell invasion. A)
Brain slice invasion assay. GFP-expressing SNB19 and U87
glioblastoma cells were transfected with siRNAs (10 nM) directed
against luciferase (control) or RhoG (two different oligos). The brain
slice invasion assay was performed as described in Materials and
Methods. Shown are the mean (+/−SEM) of three independent
experiments, each performed in triplicate. Differences between RhoG
knockdown and control are significant (p < 0.001, two-tailed t test).
B) Western blot demonstrating depletion of RhoG in SNB19 cells. C
and D) Depletion of RhoG has only a marginal inhibitory effect on
cell proliferation. SNB19 cells were transfected with siRNAs (10 nM)
directed against luciferase (control, solid squares) or RhoG (RhoG-2,
empty squares; RhoG-3, empty triangles). Cell proliferation was
quantified using the Sulphorhodamine B assay as described in
Materials and Methods, either in the presence of 10% FBS (C) or in
the absence of serum (D). Results shown represent the mean +/−
SEM for respectively 6 independent experiments (C) and 4
independent experiments (D).
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glioblastoma tumors [31,32], we also examined whether
RhoG mediates EGF-stimulated signaling in glioblast-
oma cells. We observed that EGF (50 ng/ml) signifi-
cantly activates RhoG in SNB19 cells (Figure 6A). In
addition, depletion of RhoG significantly inhibits EGF-
stimulated Rac1 activation in these cells (Figure 6B).
RhoG promotes glioblastoma cell survival
Previous studies have implicated RhoG in the regulation
of cell survival through direct binding to the regulatory
subunit of PI3K and subsequent activation of Akt
[17,33]. We therefore also examined the role of RhoG in
glioblastoma cell survival using a clonogenicity assay.
We observed that depletion of RhoG strongly inhibits
glioblastoma cell colony formation, similar to the extent
of depleting Rac1 (Figure 7), indicating a significant role
for RhoG in glioblastoma cell survival.
We also examined whether depletion of RhoG sensi-
tizes glioblastoma cells to ionizing radiation, which is
part of the current standard protocol for glioblastoma
therapy. We found that the inhibitory effect of depleting
RhoG on cell survival is additive to that of ionizing
radiation, rather than showing synergism (data not
shown), indicating that RhoG does not specifically con-
tribute to radio-resistance.
RhoG is overexpressed in human glioblastoma tissue
Available microarray expression data, such as NCBI
dataset GSE4290, did not reveal any significant change
of RhoG mRNA expression levels across non-neoplastic
brain and different grades of astrocytoma (data not
shown). However, immunohistochemical analysis
revealed prominent cytoplasmic RhoG staining (with
scores 2–3 out of 3) in glioblastoma cells in all 41 tumor
samples tested (Figure 8B). Staining is also visible in
some reactive astrocytes (Figure 8A, arrowhead), but not
in non-reactive non-neoplastic glial cells (Figure 8A,
arrow). Significant expression is also observed in endo-
thelial cells of the tumor microvasculature (Figure 8A).
However, using an astrocytoma progression tissue
microarray, we did not observe significant differences
between the staining intensity of tumor cells across dif-
ferent astrocytoma grades, including pilocytic, grade II,
anaplastic and grade IV astrocytomas (data not shown).
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Figure 2 RhoG mediates HGF-induced Rac1 activation. A) Time-dependence of RhoG activation by HGF. SNB19 cells were serum starved for
24 hours, and incubated further with or without HGF for the indicated time. Subsequently, cells were lysed and RhoG activity was determined
using an active RhoG pull down assay as detailed in Materials and Methods. Western blot shows activated RhoG and total RhoG for HGF (25 ng/
ml)-stimulated and control cells. Histogram shows quantification (+/− SEM) of at least 5 independent experiments. B) RhoG mediates HGF-
induced Rac activation. Cells were transfected with siRNAs (10 nM) directed against luciferase (control) or RhoG-2. Forty eight hours after
transfection, cells were serum starved for 24 hours, and incubated further with or without HGF for the indicated time periods. Rac activity was
determined using the Rac G-LISA Activation Assay as detailed in Materials and Methods. The results shown represent the means +/− SEM of at
least 3 independent experiments (* = p< 0.05, two-tailed t test). C) depletion of RhoG does not affect expression of Rac1 nor vice versa. Cells were
transfected with siRNAs (10 nM) directed against luciferase (control) or RhoG (two different oligos). Cells were lysed 72 hours after transfection,
followed by western blot analysis. Histograms shows quantification (+/− SEM) of between 3 and 4 independent experiments.
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Discussion
In this paper, we show that the small GTPase RhoG
plays a critical role in glioblastoma cell invasion, both in
in vitro and ex vivo settings. In addition, RhoG is im-
portant for glioblastoma cell survival, but less so for pro-
liferation. Thus, RhoG contributes significantly to the
malignant behavior of glioblastoma cells.
We also found that RhoG is activated by cMet and
EGFR, two receptors that are deregulated in glioblast-
oma tumors [31,32,34], further underlining the relevance
of RhoG-mediated signaling in the context of glioblast-
oma. Compared to other Rho family members, relatively
few receptors that stimulate RhoG activity have been
identified to date. These include ICAM-1 and syndecan
4 [35,36]. RhoG signaling also is thought to mediate sig-
naling from the fibronectin receptor [28]. Recently,
EGFR also has been shown to activate RhoG [19]. Here,
we confirm this finding in a clinically relevant setting
and add cMet to the list of receptors that stimulate
RhoG activity.
Early observations have indicated the existence of both
Rac1-dependent and Rac1-independent functions of
RhoG [27,37]. A subsequent key finding was that RhoG-
stimulated activation of Rac1 is mediated by direct inter-
action of RhoG with ELMO [28]. ELMO forms a stable
complex with the Rac GEF Dock180 that in turn acti-
vates Rac1 and regulates neurite outgrowth [28,38].
Moreover, genetic studies using C. elegans have provided
evidence that the RhoG/ELMO/Dock180/Rac1 module
is evolutionary conserved and mediates phagocytosis of
apoptotic cells [39]. RhoG also acts upstream of Rac1 in
the regulation of cell migration [18].
Here, we show that depletion of RhoG significantly
inhibits both HGF- and EGF-stimulated Rac1 activation
in glioblastoma cells, demonstrating that RhoG acts up-
stream of Rac1 in these cells. Our finding that RhoG
contributes to Rac1 activation downstream of EGFR in
glioblastoma cells however, contrasts to published obser-
vations that EGF-stimulated Rac1 activation is independ-
ent of RhoG in HeLa cells [19]. These differences may
reflect cell type-specific differences in signaling.
The inhibitory effect of RhoG depletion on Rac1 acti-
vation is only partial (approximately 40% and 60% inhib-
ition for respectively HGF- and EGF-induced Rac1
activity), indicating that cMet and EGFR also can acti-
vate Rac1 in a RhoG-independent fashion. Interestingly
however, in spite of the fact that RhoG only partially
contributes to HGF-induced Rac1 activation, the inhibi-
tory effect of depleting RhoG on glioblastoma cell inva-
sion is as large as that of depleting Rac1, indicating that
RhoG regulates glioblastoma cell invasion in both Rac1-
dependent and Rac1-independent ways. A Rac1-
independent role of RhoG in cell migration also has
been demonstrated in fibroblasts derived from Rac1
knockout mice [40]. RhoG directly binds to the p85
regulatory subunit of PI3K, leading to the activation of
Akt [17,33], presenting a possible mechanism for Rac1-
independent stimulation of invasion by RhoG. However,
we did not observe a significant effect of depleting RhoG
on HGF-stimulated Akt activation (data not shown),
suggesting the existence of additional RhoG-controlled
signaling mechanisms.
Consistent with our observations that RhoG contri-
butes to Rac1 activation by HGF, we also observed that
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Figure 3 RhoG mediates HGF-induced invasion. A) SNB19
glioblastoma cells were transfected with siRNAs directed against
luciferase (control, 20 nM), RhoG-2 (10 nM) or Rac1-1 (20 nM). Two
days after transfection, cells were serum starved overnight and
processed for the Matrigel invasion assay as described in Materials
and Methods. All invaded cells on the bottom of the filter were
counted using an inverted microscope. Data were normalized to
those of control cells. The results shown represent the means +/−
SEM of 4 independent experiments, performed in duplicate
(* = p < 0.0005, two-tailed t test). B) Western blot demonstrating
depletion of RhoG and Rac1.
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depletion of RhoG partially inhibits HGF-induced for-
mation of lamellipodia. Surprisingly however, depletion
of RhoG enhances the formation of membrane ruffle for-
mation, whereas depletion of Rac1 strongly inhibits ruf-
fling. RhoG is thought to mediate integrin signaling and
depletion of RhoG has been shown to slow down cell
spreading [18,28], which we have confirmed in glioblast-
oma cells (data not shown), suggesting that a decrease in
cell adhesion in the RhoG-depleted glioblastoma cells
may be responsible for this increase in membrane
ruffling.
Previous data from our laboratory have demonstrated
that Rac1 is critical for glioblastoma cell proliferation in
the absence, but not in the presence of serum [10].
Somewhat surprisingly, our current results do not reveal
an important role for RhoG in gliobastoma cell prolifera-
tion, neither in the absence nor in the presence of
serum. This suggests that partial inhibition of Rac1 acti-
vation is not sufficient to affect Rac1’s ability to stimu-
late cell proliferation. Interestingly, RhoG has been
implicated in the regulation of the proliferative behavior
of neural progenitor cells [21]. The stimulatory effect of
RhoG on neural progenitor cell proliferation depends on
PI3K activation, but not on the interaction of RhoG with
ELMO, suggesting that this effect is independent of
RhoG-mediated activation of Rac1.
Several observations in the literature have shown a
strong correlation between tumor cell invasiveness and
survival potential, both in glioblastoma [41,42] and
breast cancer [43], suggesting the existence of signaling
nodes that coordinate tumor cell invasion with survival.
Thus, our observations that both RhoG and Rac1
significantly inhibit glioblastoma cell colony formation,
identify these GTPases as such signaling nodes. We
hypothesize that these invasion/survival signaling nodes
present attractive targets for therapeutic intervention.
Conclusions
Our functional analysis of RhoG in the context of glio-
blastoma has revealed a critical role for RhoG in tumor
cell invasion and survival. Furthermore, our findings that
RhoG is overexpressed in human glioblastoma tumors
and that this GTPase is activated by signaling pathways
that are hyperactive in glioblastoma tumors, provide a
strong indication for the use of RhoG and elements of
RhoG-regulated signaling pathways as novel drug targets
for the treatment of glioblastoma. It will be interesting
to see whether these findings extend to other tumor
types. Importantly, RhoG, in contrast to Rac1, appears
to play restricted roles in normal cells, which is
supported by the fact that RhoG knockout mice are
developmentally normal and display only minor im-
munological phenotypes [44]. This suggests that inhibi-
tors of RhoG signaling should display a relatively large
therapeutic window. Notably, GTPases are thought to
be challenging drug targets [45]. However, over the
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Figure 4 Rac1-mediated invasion depends on a threshold of Rac1 expression. A) Rac1 siRNA-concentration dependence of cell invasion.
SNB19 cells were transfected with the indicated Rac1 siRNA concentrations and invasion assays were performed as in Figure 3. The results shown
represent the means +/− SEM of 4 independent experiments, performed in duplicate. Data were normalized to those of control cells. B) Rac1
siRNA-concentration dependence of Rac1 activation state. Cells were transfected with the indicated Rac1 siRNA concentrations and Rac activity
was determined as in Figure 2B. The results shown represent the means +/− SEM of 5 independent experiments. C and D) Rac1 siRNA-
concentration dependence of Rac1 expression. C) Representative western blot demonstrating siRNA-dependent depletion of Rac1. D)
Quantification of western blots for experiments shown in A) and B). The results shown represent the means +/− SEM of 8 independent
experiments. Data were normalized to those of control cells.
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past several years, a number of different avenues have
opened up, mostly focusing on the Rac1 GTPase as a
target, including structure-based virtual screening, the
development of peptidic structures and the implemen-
tation of siRNA delivery [46-52]. This wide range of
approaches is also applicable to RhoG, and it is hoped
that future efforts will yield RhoG-specific inhibitors.
Methods
siRNAs
Two siRNA duplexes targeting RhoG were used, a 21
nucleotide siRNA with target sequence 5'- GCAA-
CAGGATGGTGTCAAG-3' [35] was purchased from
Ambion and a 27 nucleotide siRNA with target sequence
5'- CACUUCCUUGACACCAUCCUGUUGCAG' was
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against luciferase (control, 20 nM), RhoG-2 (10 nM) or Rac1 (20 nM). Two days after transfection, cells were plated on laminin-coated coverslips
and serum starved overnight. Subsequently, cells were incubated with DMEM (untreated) or stimulated 4 min with DMEM containing 25 ng/ml
HGF and processed as described in Materials and Methods. Scale bar represents 10 μm. Lamellipodia are indicated by an arrowhead. Ruffles are
indicated by arrows. B) Quantification of lamellipodia and ruffle formation. Presented are mean values (+/− SEM) for approximately 35 cells per
condition. The results shown are representative of two independent experiments. C) RhoG is necessary for invadopodia formation. SNB19 cells
were transfected with siRNA (20 nM) directed against luciferase (control), RhoG-2 or Rac1-1. Forty eight hours after transfection, cells were split to
a new dish for another 24 hours prior to plating on FITC-gelatin coated coverslips for 16 to 18 hours. Invadopodia formation was determined as
described in Materials and Methods. For each condition, 16 (60x) fields were quantified, comprising a total of approximately 30 cells. The results
shown represent the means +/− SEM of 5 independent experiments (*p < 0.05 and **p < 0.0005, two-tailed t test).
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purchased from Integrated DNA Technologies. A control
siRNA directed against GL2 luciferase with target
sequence 5'- AACGTACGCGGAATACTTCGATT was
purchased from Ambion. The Rac1 siRNAs have been
described previously [10]. Depletion of the respective
proteins was confirmed by western blotting using mono-
clonal antibodies against Rac (clone 23A8, Upstate Bio-
technology) and RhoG (clone 1 F3 B3 E5, Millipore). A
monoclonal antibody against α-tubulin (Sigma) was used
as loading control.
Cell culture and siRNA transfections
Cells were grown at 37°C in the presence of 5% CO2 in
DMEM supplemented with 10% FBS and penicillin/
streptomycin. Transient transfection of siRNA was car-
ried out with Dharmafect (Dharmacon) solution #1 at
1 μl/ml, using the protocol provided by the manufac-
turer. Cells were assayed, typically 3–4 days after trans-
fection, when maximal knockdown was observed.
RhoG activity assay
RhoG activity was measured essentially as described pre-
viously [53]. GST-ELMO-NT (GST fusion protein con-
taining the N-terminal RhoG-binding domain of
ELMO2, amino acids 1– 362) was expressed in Escheri-
chia coli (BL21) and purified using a B-PER GST fusion
protein purification kit (Thermo scientific). Purified
GST-ELMO NT was stored in 100 mM Tris–HCl, pH
7.5, 2 mM MgCl2 and 0.1 mM DTT, at −80°C. To meas-
ure RhoG activity, SNB19 cells grown in 10 cm dishes
were serum starved for 24 hours and stimulated with ei-
ther 25 ng/ml HGF or 50 μg/ml EGF for various times.
Subsequently, cells were washed with 10 ml of cold PBS
and lysed in ice-cold cell lysis buffer (50 mM Tris–HCl,
pH 7.5, 100 mM NaCl, 10 mM MgCl2, 1% Triton X-100,
10% glycerol, 1 mM DTT and protease inhibitor cocktail
(Roche). Cell lysates were centrifuged for 2 minutes at
13,000 g at 4°C. For each condition, 500 mg of super-
natant was incubated with 20 μg of GST-ELMO-NT and
10 μl of GST beads for 1 hour at 4°C. The beads were
washed with lysis buffer and bound proteins were ana-
lyzed by western blotting using a monoclonal anti-RhoG
antibody (Millipore). Semi-quantification of RhoG
Figure 8 RhoG is strongly expressed in glioblastoma tumors. A) Representative RhoG immunohistochemistry micrograph of reactive tissue
adjacent to tumor. “V” indicates vessel, arrows indicate normal glial cells and arrowheads point to reactive astrocytes in the tumor rim. B)
Representative RhoG immunohistochemistry micrograph of tumor core. Scale bar represents 100 μm.
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Figure 7 RhoG and Rac1 contribute to glioblastoma cell
clonogenicity. A) Colony formation assay. SNB19 cells were
transfected with siRNAs (10 nM) directed against luciferase (control),
RhoG or Rac1. Colony formation assays were performed as described
in Materials and Methods. The results shown represent the means
+/− SEM of 4 independent experiments (each performed in
quadruplet dishes) for the RhoG and 3 independent experiments for
the Rac1 knock-downs (p < 0.001, two-tailed t test). B) Western blot
demonstrating depletion of RhoG and Rac1.
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activity was performed by gel-scanning, determining the
amount of RhoG bound to GST-ELMO-NT normalized
to the amount of total RhoG present in cell lysates.
Rac activation assay
Rac activation was determined using the Rac G-LISA
Activation Assay (Cytoskeleton) according to the manu-
facturer’s recommendations. In brief, SNB19 cells were
transfected with control or RhoG siRNA. 48 hours after
transfection, cells at 60-70% confluency were serum
starved for 24 hours and treated with either HGF or
EGF. Subsequently, cells were washed with ice-cold PBS,
followed by lysis at 4°C. Cell lysates were clarified by
centrifugation at 13,000 g at 4°C for 2 minutes and snap
frozen in liquid nitrogen. For each condition, 50 μl of
cell lysate (containing 25 μg of protein) was added to a
single well of the Rac GTPase binding plate. Further
steps were carried out exactly as described in the proto-
col provided by the manufacturer.
Brain slice invasion assay
The brain slice invasion assay was performed as
described previously [20], with minor modifications. In
brief, 24 hours after transfection, GFP-labeled cells were
deposited bilaterally onto the putamen of 400 μm thick
slices of freshly isolated 4–6 week-old mouse brains. Ser-
ial Z-sections were collected by confocal laser scanning
microscopy and the extent of invasion was determined as
the maximum depth of invasion of the glioblastoma cells.
Matrigel invasion assay
First, the bottom side of the filter (8 μm pore size) was
coated with a thin layer of fibronectin by overlaying with
a drop of fibronectin (1 μg/ml) for 1 hour at room
temperature, followed by rinsing with PBS. Subsequently,
9 x 104 glioma cells were suspended in 50 μl of Matrigel
kept at 4°C (10 mg/ml) (Trevigen) and added to the top
well (insert) of a 24-well transwell plate (BD). The matrix
was allowed to solidify at 37°C for 30 minutes. Next,
200 μl of serum-free DMEM medium was added to the
top well and 700 μl of serum-free DMEM containing
HGF (25 ng/ml) to the bottom well. After 24 – 48 hours
of incubation, the insert was fixed in 4% formaldehyde/
PBS and stained with crystal violet. Subsequently, cells on
the upper surface of the filter were wiped off with a Q-tip
and cells attached to the bottom side of the filter counted
under the microscope (Olympus IX70, 20x objective).
Quantification of lamellipodia formation
Serum-starved cells plated on laminin–covered cover-
slips (Becton Dickinson) were incubated with DMEM
(control) or stimulated for 4 minutes with DMEM con-
taining 25 ng/ml HGF. Subsequently, cells were fixed in
4% formaldehyde/PBS, permeabilized with 0.1% Triton-
X100 dissolved in PBS and incubated with Rhodamine-
conjugated phalloidin (Molecular Probes) to stain for F-
actin. Processed coverslips were mounted in 75% Vecta-
shield mounting medium (Vector Laboratory). Images
were collected using a Zeiss Axiovert 200 M microscope,
equipped with a 63x objective, a cooled CCD camera
(AxioCam monochromatic) and Axiovision 4.7 image
analysis software. For each experimental condition,
images were taken in a random fashion. Lamellipodia
and ruffles were traced using Image J software. For each
cell, the fraction of the cell perimeter that displays either
lamellipodia or ruffles was calculated.
Sulphorhodamine B assay
Cell proliferation was measured using the sulphorhoda-
mine B colorimetric assay [54]. Briefly, one day after
siRNA transfection, cells were seeded in septuplet in 96-
well microtiter plates in serum-containing medium at
2.5 x 103 cells/well for determining growth in the pres-
ence of serum and at 5 x 103 cells/well for determining
growth in the absence of serum. Once the cells attached
and spread (5 hours after plating), for a subset of the
wells, the medium was replaced with serum-free
medium. At various times, cells were fixed in 10%
trichloroacetic acid for 1 hour at 4°C, rinsed and subse-
quently stained for 30 minutes at room temperature
with 0.2% SRB dissolved in 1% acetic acid, followed by
air drying. The bound dye was solubilized in 200 μl of
10 mM unbuffered Tris base for 30 minutes and the OD
was read at 490 nm in an ELISA plate reader.
Invadopodia formation assay
FITC-gelatin coated coverslips were prepared as
described previously [55], with minor modifications.
Briefly, in a 20 mg/ml gelatin solution (300 bloom gel-
atin in 50 mM Na2B4O7/40 mM NaCl, pH 9.3), FITC
(Sigma-Aldrich, St. Louise, MO) was added to a 0.2 mg/
ml final concentration for two hours, followed by dialysis
against PBS for 2 to 3 days at 37°C. Thin layers of
FITC–conjugated gelatin were placed on coverslips,
cross-linked with 0.8% glutaraldehyde for 10 minutes on
ice, followed by 30 minutes at room temperature. Subse-
quently, coverslips were incubated with 5 mg/ml of so-
dium borohydride for 3 minutes and sterilized with 70%
ethanol for 10 minutes. Sterilized FITC-gelatin coated
coverslips were left dry for at least 15 minutes in the tis-
sue culture hood. One hour before plating the cells, cov-
erslips were re-hydrated with DMEM containing 10%
fetal bovine serum at 37°C. Cells were cultured on the
FITC-gelatin coverslips in DMEM, supplemented with
0.5% FBS, for 16 to 18 hours. Subsequently, the cells
were fixed and processed for immunofluorescence as
described in the section on quantification of lamellipodia
formation. Invadopodia formation was determined by
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counting the percentage of cells that had an associated
area of matrix degradation.
Colony formation assay
Forty eight hours after transfection, SNB19 cells were
seeded in 6 cm plates at a density of 300 cells per dish.
The cells were incubated for 12 days, with medium
changes every 3 or 4 days. Plates were fixed in formalde-
hyde solution (4%) and colonies were stained with sul-
phorhodamine B (see above). The plates were imaged
using a scanner and colonies were counted using Adobe
Photoshop CS3 Extended Edition or ImageJ, with a
threshold that corresponds to 50 cells/colony.
Immunohistochemistry
The tissue microarray and immunohistochemistry pro-
cedures that we have used to examine RhoG expression
in the rim and core of glioblastoma tumors have been
described previously [56].
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